Når Atripla anvendes i et regime med lav- dosis ritonavir, bør muligheden for øget incidens af efavirenz- associerede bivirkninger overvejes p. g. a. mulig farmakodynamisk interaktion.
When using Atripla in a regimen including low-dose ritonavir, the possibility of an increase in the incidence of efavirenz-associated adverse events should be considered, due to possible pharmacodynamic interaction.